stockrow
Friday 6 November 2026
Export AUPH’s income statement to Excel — free account
Aurinia Pharmaceuticals Inc
AUPH Healthcare Biotechnology
Aurinia Pharmaceuticals Inc’s revenue for fiscal 2025 (year ended December 2025) was $283.1 million, up 20.4% from fiscal 2024.
- Revenue
- +13.9%
- EPS
- 0.00%
- Free cash flow
- +4.41%
- Total debt
- −30.0%
Quarter to September 2026, against a year earlier
16.40
0.19
+1.17%
Follow AUPH
Alert me
| Older periods | Dec '25 | Mar '26 | Jun '26 | Sep '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
7.35 | 6.56 | 7.10 | 6.78 |
P/S ratio |
7.57 | 6.58 | 7.09 | 6.72 | |
P/FCF ratio |
15.83 | 11.77 | 12.61 | 12.21 | |
P/Operating CF |
46.93 | 60.25 | 41.99 | 46.62 | |
P/B ratio |
3.69 | 3.46 | 3.59 | 3.29 | |
Price to Tangible BV |
3.71 | 3.48 | 3.61 | 3.30 | |
EV/Sales |
6.35 | 5.47 | 5.81 | 5.33 | |
EV/EBITDA |
13.42 | 10.93 | 11.30 | 10.49 | |
EV/Operating CF |
13.25 | 9.77 | 10.32 | 9.67 | |
EV/FCF |
13.27 | 9.79 | 10.33 | 9.68 | |
Quick Ratio |
4.69 | 4.94 | 4.85 | 5.57 | |
Current Ratio |
5.25 | 5.55 | 5.42 | 6.12 | |
Net Debt/EBITDA |
(10.47) | (7.11) | (8.88) | (11.50) | |
Debt/Assets |
6.96% | 6.65% | 5.55% | 4.73% | |
Debt/Equity |
0.09 | 0.08 | 0.07 | 0.06 | |
Asset Turnover |
0.43 | 0.49 | 0.48 | 0.48 | |
Operating CF/Net income |
0.22 | 0.95 | 1.41 | 1.46 | |
Capex/Depreciation |
(0.01) | (0.01) | 0.00 | 0.00 | |
Interest Coverage |
26.90 | 41.21 | 42.31 | 39.33 | |
Research and Development Expense of Revenue |
14.13% | 9.61% | 15.68% | 19.85% | |
Selling, General and Administrative Expense of Revenue |
37.94% | 28.35% | 28.25% | 29.49% | |
Intangible Assets out of Total Assets |
0.01 | 0.01 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
8.72% | (1.11%) | 3.41% | 7.32% | |
Graham Net Nets |
0.15 | 0.17 | 0.16 | 0.19 | |
Graham Number |
14.53 | 14.77 | 15.94 | 16.28 | |
Earnings Yield |
13.61% | 15.25% | 14.08% | 14.75% | |
Free Cash Flow Yield |
6.32% | 8.49% | 7.93% | 8.19% | |
Revenue per Share |
0.57 | 0.59 | 0.64 | 0.63 | |
Operating CF per Share |
0.34 | 0.25 | 0.40 | 0.35 | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
0.34 | 0.25 | 0.40 | 0.35 | |
Cash per Share |
2.96 | 2.86 | 3.41 | 3.65 | |
Shareholders Equity per Share |
4.33 | 4.29 | 4.73 | 4.93 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
4.33 | 4.29 | 4.73 | 4.93 | |
Free Cash Flow |
45.60 | 32.52 | 52.57 | 46.34 | |
Working Capital |
398.24 | 393.69 | 441.43 | 491.88 | |
Capital Expenditures |
(0.07) | (0.04) | 0.00 | (0.02) | |
Net Current Asset Value |
321.71 | 323.87 | 363.93 | 419.70 | |
EV/EBIT |
15.71 | 12.56 | 12.86 | 11.90 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | |
Price to Operating Income |
18.73 | 15.11 | 15.70 | 15.00 | |
| Other line items | |||||
Average Receivables |
39.00 | 44.76 | 40.61 | 39.07 | |
Average Payables |
4.25 | 3.44 | 2.52 | 2.61 | |
Average Inventory |
42.46 | 46.30 | 45.83 | 44.26 | |
Average Assets |
651.12 | 614.42 | 647.41 | 676.62 | |
Average Common Equity |
479.40 | 458.91 | 475.08 | 511.65 |
Columns are period end dates · fundamentals updated 5 Nov 2026